BACKGROUND: Hypertrophic cardiomyopathy (HCM) is frequently caused by mutations in myosin-binding protein C3 (MYBPC3) resulting in a premature termination codon (PTC). The underlying mechanisms of how PTC mutations in MYBPC3 lead to the onset and progression of HCM are poorly understood. This study's aim was to investigate the molecular mechanisms underlying the pathogenesis of HCM associated with MYBPC3 PTC mutations by utilizing human isogenic induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs).
H
ypertrophic cardiomyopathy (HCM) is the most common inherited heart disease, with a prevalence of 1 in 500 in the population. 1 Generally, HCM is characterized by various degrees of left ventricular wall thickening, diastolic dysfunction, progressive heart failure, and sudden cardiac death. HCM is predominantly caused by mutations in myosin heavy chain 7 (MYH7) and myosin-binding protein C3 (MYBPC3); the majority of mutations in MYBPC3 result in premature termination codons (PTCs). 2 Previous studies suggest that MYBPC3 PTC mutations are associated with low mRNA and absent truncated peptides derived from the diseased allele because of the activation of the nonsense-mediated decay (NMD) pathway and the ubiquitin-proteasome system (UPS), respectively, resulting in haploinsufficiency of the healthy allele. 3, 4 Despite the progress in understanding the pathogenesis of HCM, the underlying molecular mechanisms that link PTC mutations in MYBPC3 to HCM onset and progression are incompletely understood.
In recent years, the emergence of human induced pluripotent stem cell (iPSC) and genome editing technologies has dramatically advanced disease modeling of cardiomyopathies in vitro. 5 Combining iPSC technology and genome editing now provides new opportunities for a better understanding of the molecular mechanisms underlying the pathogenesis of genetic HCM in vitro. [6] [7] [8] To study the molecular mechanisms of HCM associated with MYBPC3 PTC mutations, we generated isogenic iPSC-derived cardiomyocytes (iPSC-CMs) by either correcting PTC mutations (p. 943x; p.R1073) in iPSCs derived from patients with HCM or introducing a PTC mutation (p.R943x) into a healthy iPSC line. We performed structural and functional analyses to investigate the HCM phenotypes in vitro and observed aberrant calcium handling properties in HCM iPSC-CMs compared with their respective isogenic controls in vitro. Although MYBPC3 mRNA expression levels were significantly reduced in HCM iPSC-CMs, we observed no haploinsufficiency of MYBPC3 at the protein levels when compared with isogenic controls. Transcriptomic analysis revealed a molecular HCM signature characterized by activation of pathways associated with cardiac hypertrophy, calcium signaling, translation, RNA metabolism, and the NMD. Molecular inhibition of the NMD pathway in HCM iPSC-CMs carrying the MYBPC3 p.R943x mutation resulted in the reversal of the molecular phenotype and normalization of calcium handling kinetics, suggesting a direct connection between the constitutively activated NMD pathway and the molecular mechanisms associated with the pathogenesis of HCM.
METHODS
A full description of the Methods is presented in the onlineonly Data Supplement section. The data, analytic methods, and study materials are available to other researchers for purposes of reproducing the results or replicating the procedures on request. The iPSC lines have been deposited to the Stanford's Cardiovascular Institute iPSC Biobank and are available to other researchers upon request.
iPSC Generation and Cardiac Differentiation
Patients and healthy controls ( Figure IA in the online-only Data Supplement) were enrolled in the study with informed consent. The study was approved by the Stanford Institutional Review Board and Stem Cell Research Oversight Committee. Peripheral blood mononuclear cells were collected and subsequently reprogrammed using the nonintegrating Sendai virus (CytoTune-iPS 2.0 Sendai Reprogramming Kit, Thermo Fisher Scientific). A single-nucleotide polymorphism array (OmniExpress24, Illumina) was used to assess the karyotype of the iPSC clones, and one clone per iPSC line was chosen for subsequent studies. All experiments were performed using iPSC-CMs generated from iPSCs with passage numbers between 18 and 35. Differentiation into iPSC-CMs was performed using a monolayer small-molecule Wnt-activation/ inhibition protocol. 9 Beating iPSC-CMs were maintained in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with B27 supplements (Thermo Fisher Scientific). All experiments were performed between days 35 and 50 after initiation of differentiation. Dissociation of iPSC-CMs was performed using prewarmed TrypLE select 10x (Thermo Fisher Scientific) at 37°C. After detaching, cells were collected using What Are the Clinical Implications?
• The study offers a novel perspective on potential therapies for genetic hypertrophic cardiomyopathy.
• Strategies targeting the nonsense-mediated decay pathway might prove successful in halting the inevitable progression of hypertrophic cardiomyopathy. 
Genome Editing
Genome editing was performed using the engineered nucleases TALEN (Transcription Activator-Like Effector Nucleases) or CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats/Cas9) as previously described. 6, 10, 11 For genome editing, the respective iPSC lines were used at passage numbers between 20 and 25. Expanded Methods can be found in the online-only Data Supplement.
Droplet Digital Polymerase Chain Reaction
Droplet digital polymerase chain reaction (ddPCR) was performed based on the ddPCR Applications Guide (BioRad). To establish the specificity of the primer and probe combinations and the optimal annealing temperature, gBlocks (IDT) were used with either the healthy or mutant cDNA sequence. Total RNA was extracted from iPSC-CMs and reverse transcribed, and 1 ng of RNA-equivalent cDNA was mixed with primers, probes, and ddPCR Supermix reaction (total volume 20 μL; BioRad). Droplet formation was carried out using a BioRad QX100 droplet generator. PCR amplification was performed and samples were analyzed using a BioRad QX100 reader. The following probes and primers were used: MYBPC3_943: FW: CACACATCGATACTGGTGAAGG; REV: GCTCCGTGGTGGTAA CAG; wild-type probe: FAM-TTTCCGAGTGCGGGCACACAATAT-black hole; mutant probe: hex-TTTCTGAGTGCGGGCACACAATAT-black hole.
MYBPC3_1073: FW: TTGTTGACAAGCCAAGTCCT; REV: CTCCATGGTCTTCTTGT CGG; wild-type probe: FAM-TCCGGGTGACTGACGCCTGGGGT-black hole; mutant probe HEX-TCCCGGGTGACTGACGCCTGGGGT-black hole.
RNA Sequencing
Sequencing libraries were generated using the NEBNext Ultra Directional RNA Library Prep Kit for Illumina. Clustering of the index-coded samples was performed on a cBot Cluster Generation System using TruSeq PE Cluster Kit v3-cBot-HS (Illumina). Sequencing was carried out on an Illumina HiSeq platform. For each sample in the whole transcriptome sequencing library, 30 to 40 million 150-base pair pairedend reads were acquired from the sequencer. Raw sequence data were checked for quality with FastQC (version 0.11.5), and results were aggregated with MultiQC. Sequence data were aligned to the human genome (hg19) using STAR (version 2.5.1b) with ENCODE options for long RNA-seq pipeline. Alignment results were assessed using Samtools and aggregated with MultiQC (version 0.9). Uniquely mapped reads were quantified using featureCounts (version 1.28.0), and differentially expressed genes were identified using DESeq2 (version 1.18.1). The DESeq2 Bioconductor package was used to identify genes that were differentially expressed between groups. 12 Pairwise comparisons between groups were conducted by applying the Wald test of the negative binomial distribution to the log 2 gene counts, and then the BenjaminiHochberg correction was applied. A significant regulation was suggested with a fold change of ±1.4 and a q value <0.05. The expression of wild-type versus mutant MYBPC3 mRNA was assessed using the Integrative Genomics Viewer (Broad Institute).
Contractility Assays
Throughout the study, contraction analysis was performed using a high-speed video microscopy, followed by motion vector analysis to investigate the contractile characteristics of iPSC-CM monolayers. Depending on the design of the experiment, iPSC-CMs were seeded at 2x10 5 cells/cm 2 into 384-or 96-well plates. Contractility was measured using the Sony SI8000 cell motion imaging system. Video imaging of beating iPSC-CMs was recorded for 10 seconds at a frame rate of 75 fps, a resolution of 1024×1024 pixels, and a depth of 8 bits using a ×10 objective on a fully automated Nikon microscope (Eclipse Ti, Nikon). Motion detection and analysis were performed using the Sony Cardio-analysis software (based on a block-matching algorithm). 13 For stress experiments, iPSC-CMs were treated with the following options: 30 nmol/L triiodothyronine, 1 µmol/L dexamethasone, and 20 ng/µL insulin-like growth factor 1 (IGF1) for 72 hours (all Sigma Aldrich); 25 nmol/L digoxin for 3 days (Sigma Aldrich); 1 nmol/L digoxin for 7 days; and 10 µmol/L phenylephrine, 25 pg/mL endothelin-1, and 100 nmol/L isoproterenol for 7 days (all from Sigma Aldrich).
Preparation and Culture of Engineered Heart Tissues
Engineered heart tissues (EHTs) were prepared using a fibrin gel as previously described.
14 Briefly, EHTs were produced around silicone posts in agarose-casting molds in a 24-well plate. Each EHT contained 1x10 6 iPSC-CMs in a fibrin matrix (100 µL total) composed of 10 µL Matrigel (Corning), 5 mg/mL bovine fibrinogen (2.53 µL of 200 mg/mL fibrinogen reconstituted in 0.9% NaCl), and supplemented with 0.1 mg/ mL aprotinin (Sigma Aldrich), 5.57 µL of 2× high-glucose DMEM with 10% horse serum and 1% penicillin/streptomycin (Thermo Fischer Scientific), 78.8 µL of high-glucose DMEM (Thermo Fischer Scientific) with 10% FBS and 1% l-glutamine (Invitrogen), 10 µmol/L Y-27632, and 3 U/mL thrombin (Sigma). EHTs were incubated for 2 hours at 37 o C and then transferred to a new plate containing RPMI supplemented with B27 supplement and 10% KnockOut serum replacement (Thermo Fischer Scientific). The medium was replaced every 2 days with RPMI+B27 with 33 µg/mL aprotinin.
Contractile Analysis of EHTs
EHT contractile motion was recorded using the SI8000 Cell Motion Imaging System (Sony). The SI8000R Analyzer Software (Sony) was used to detect motion vectors and track the movement of each EHT post. The distance of maximum after deflection from rest was extracted from each contraction cycle in the tracking data using a custom MATLAB script. Deflection was converted to force using the equation for deflection of an end-loaded cantilever beam with an elastic modulus of 1.7 MPa, a radius of 0.5 mm, and a length of 10 mm. 
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Ca
2+ Imaging
Ratiometric calcium imaging was performed on iPSC-CMs loaded with Fura-2 under continuous electric stimulation with excitation wavelengths at 340 and 380 nm. Raw data exported from Nikon NIS-Elements were analyzed using a custom Python script (https://github.com/GeorgeMcMullen/ CalciPy) 15 built specifically to automate processing of ratiometric calcium imaging data for high-throughput analysis. An expanded description can be found in the online-only Data Supplement.
Nanofluidics Immunoassay
Nanofluidics immunoassay was performed on a Peggy Sue system (ProteinSimple; Bio-Techne). The primary antibodies anti-MYBPC3 (Abgent) and anti-αSA (Abcam) were diluted to be used in a final dilution of 1:50. The determination of the sizes, areas, heights, and signal-to-noise ratios of MYBPC3 and αSA proteins was automatically performed on the Compass for Simple Western software (version 3.1.7). A detailed protocol is outlined in the expanded Methods in the online-only Data Supplement.
Mass Spectrometry
Protein lysates from isogenic lines (943cor and 943het iPSCCMs, as well as ctrl and ctrl943 iPSC-CMs) were obtained from 4 independent differentiation batches. After protein digestion and labeling with 10-plex tandem mass tags (Thermo), mass spectrometry was performed using a Thermo Orbitrap Fusion high-resolution mass spectrometer. A detailed protocol is outlined in the expanded Methods in the online-only Data Supplement.
cDNA Overexpression of Healthy and Mutated MYBPC3
Healthy MYBPC3 cDNA in a pCMV-SPORT6 vector was obtained as glycerol stock from Dharmacon (MHS6278-202800272). The plasmid was transformed into competent cells (Zymo Research) and plated overnight. After colony picking, plasmid extraction was performed (Plasmid Miniprep Kit, Qiagen), and the vector was sequence validated by Sanger sequencing. Before final use, the clone was expanded and plasmid extraction was performed (Plasmid Midiprep Kit, Qiagen). Mutagenesis of the wild-type MYBPC3 cDNA vector to introduce the p.R943x mutation was performed using the QuikChange Lightning Site-Directed Mutagenesis Kit according to the manufacturer's protocol (Agilent). Wild-type or mutated vectors (1 µg) were transfected into HEK293T cells using Lipofectamine 3000 according to the manufacturer's protocol (Thermo Fisher Scientific). Protein expression was evaluated 72 hours after transfection.
Small-Interfering RNA-Mediated Knockdown
Gene knockdown experiments were performed using Lipofectamine RNAiMax (Life Technologies) according to the manufacturer's instructions. Cells were transfected with either scrambled or small-interfering RNA against UPF1 (smallinterfering GENOME small-interfering RNA, GE Healthcare Dharmacon, 25 nmol/L) for 48 hours before being subjected to subsequent downstream analyses.
Statistical Analysis
Data analysis was performed using Microsoft Excel and Graphpad Prism5 software. Heat maps were generated using a web-based tool https://software.broadinstitute. org/morpheus/. 16 For statistical analysis, Student t test was used to compare differences between 2 datasets. For comparisons among multiple groups, 1-way ANOVA was used, and Bonferroni post hoc test was used for comparisons of all groups depending on the properties of the datasets. For datasets with 2 factors, 2-way ANOVA was used to calculate the significance of the source of variation. Once a significant variation by treatment and interaction of the 2 factors was confirmed, the positive differences in increase between treatments were analyzed by 1-way ANOVA. Correlation analysis was performed using Spearman's rank test. Overall, a P value <0.05 was considered statistically significant. All data in bar graphs are presented as mean±SD unless indicated otherwise.
RESULTS
Generation of Isogenic iPSC Lines With
MYBPC3 Truncation Mutations
To study PTC mutations in MYBPC3 in the pathogenesis of HCM, we enrolled a patient diagnosed with a severe hypertrophic phenotype of HCM as well as with a positive family history of HCM, carrying a heterozygous mutation in MYBPC3 resulting in a PTC in exon 27 (c. 2827 C>T; p.R943x [943het]; Figure 1A and Figure IA and IB in the online-only Data Supplement). To generate isogenic iPSC lines, we corrected the mutation in the patient's iPSCs (943cor) and also introduced the mutation in the healthy allele to obtain an iPSC line homozygous for the p.R943x mutation (943hom; Figure 1B) . We also introduced a heterozygous p.R943x mutation into a healthy control iPSC line (ctrl943 and ctrl, respectively; Figure IA and IE in the online-only Data Supplement).
Two additional unrelated patients were enrolled, 1 carrying the same MYBPC3 mutation (943het2) and 1 with a p.R1073P_Fsx4 mutation in MYBPC3 (1073het; Figure IA and IB in the online-only Data Supplement). These iPSC lines were also successfully corrected using CRISPR/Cas9-mediated genome editing (943cor2 and 1073cor, respectively; Figure IA and IF in the online-only Data Supplement).
Structural and Functional Phenotype of HCM iPSC-CMs
The pathological hallmarks of HCM at the histological level are myocyte hypertrophy, myocardial disarray, and interstitial fibrosis. 17 To analyze the sarcomeric integrity, ORIGINAL RESEARCH ARTICLE no significant differences in the cell size of iPSC-CMs among all isogenic comparisons ( Figure 1G and Figure  IID and IIE in the online-only Data Supplement), corroborating the findings of a recent study. 20 Taken together, these data suggest that the investigated MYBPC3 PTC mutations do not cause any structural abnormalities at the sarcomeric level and do not significantly increase the cell size in iPSC-CMs in vitro.
Recent studies have provided evidence for impaired contractile force generation in cardiomyocytes from patients with HCM harboring MYBPC3 mutations. 21 To evaluate the contractile function in our study, monolayers of isogenic iPSC-CMs were analyzed using vector-based motion detection. 13 We observed no significant differences in contractility between 943cor and 943het iPSC-CMs (Figure 2A ) or between ctrl and ctrl943 iPSC-CMs ( Figure IIIA in the onlineonly Data Supplement). A recent report suggests that HCM iPSC-CMs harboring a MYBPC3 PTC mutation (c.2373_2374insG) treated with dexamethasone, triiodothyronine, and IGF1 showed significantly lower response in contractile force generation than nonisogenic controls. 20 Treatment with dexamethasone/ triiodothyronine/IGF1 resulted in a uniform contractile response in both healthy and heterozygous iPSC-CMs ( Figure 2B and Figure IIIB in the online-only Data Supplement). However, the contractile response to treatment was blunted in 943hom iPSC-CMs ( Figure 2B ). Furthermore, we observed similar contractile responses in isogenic iPSC-CMs exposed to inotropic agents, including isoproterenol, phenylephrine, endothelin-1/ IGF1, and digoxin ( Figure IIIC and IIID in the onlineonly Data Supplement). To measure absolute forces, we generated 3-dimensional EHT constructs from all isogenic lines ( Figure IIIE in the online-only Data Supplement). 14 We observed no significant differences in force generation within isogenic comparisons of EHTs between heterozygous and healthy iPSC-CMs (Figure IIIF in the online-only Data Supplement). However, EHTs generated from homozygous iPSC-CMs (943hom) showed significantly impaired force generation ( Figure IIIF in the online-only Data Supplement). Taken together, these data suggest the absence of a significant contractile phenotype in iPSC-CMs carrying a heterozygous MYBPC3 PTC (p.R943x or p.R1073P_ Fsx4) mutation in vitro.
As alterations in calcium (Ca 2+ ) cycling are a hallmark of HCM, 22, 23 we next compared the calcium handling properties of isogenic iPSC-CMs. We observed both elevated diastolic Ca 2+ levels and prolonged relaxation kinetics in 943het compared with 943cor iPSC-CMs that were exacerbated in 943hom iPSC-CMs (Figure 2C) . Similarly, the relaxation kinetics were consistently impaired in all other HCM iPSC-CMs when compared with their respective isogenic controls (ctrl943 versus ctrl, 943het2 versus 943cor2, and 1073het versus 1073cor; Figure IVA , IVC, and IVE in the onlineonly Data Supplement). In accordance, the expression of ATP2A2, which encodes for sarco/endoplasmic reticulum calcium ATPase cardiac isoform 2a, was significantly downregulated in HCM iPSC-CMs when compared with the respective isogenic controls (Figure 2D and Figure IVB , IVD, and IVF in the online-only Data Supplement). Taken together, these results suggest that both p.R943x and p.R1073P_Fsx4 MYBPC3 PTC mutations induce calcium cycling abnormalities in HCM iPSC-CMs in vitro.
PTC Mutations Do Not Result in MYBPC3 Protein Haploinsufficiency in Isogenic iPSC-CMs
The prevailing hypothesis is that MYBPC3 PTC mutations induce MYBPC3 protein haploinsufficiency, 3 and recent studies suggest that the MYBPC3 mutant mRNA is degraded via the NMD pathway. 4 We observed that the total MYBPC3 mRNA expression was reduced by 45% and 76% in 943het and 943hom iPSC-CMs, respectively, when compared with 943cor iPSC-CMs ( Figure 3A) . Similarly, we observed a significantly reduced expression of MYBPC3 mRNA in the other isogenic comparisons (ctrl943 versus ctrl, 943het2 versus 943cor2, and 1073het versus 1073cor; Figure VA and VC in the online-only Data Supplement). In addition, the mRNA expression levels of other sarcomeric genes, such as TNNT2 and MYH7, were comparable in 943cor and 943het iPSC-CMs, but were significantly increased in 943hom iPSC-CMs ( Figure 3B ). Because the fraction of MYBPC3 mRNA carrying a PTC mutation has been shown to be reduced in HCM patient-derived samples, 3 we next quantified the expression of healthy and mutated alleles in HCM iPSC-CMs. In HCM iPSC-CMs, 27.7±4.4% of total MYBPC3 mRNA was generated from the mutated allele (943het, Figure 3C ; 943het2 and 1073het, Figure VD in the online-only Data Supplement), whereas this fraction was 13.5±4.7% in ctrl943 iPSC-CMs (Figure VB in the online-only Data Supplement), indicating the degradation of the mutant mRNA. At the protein level, we observed comparable expression of MYBPC3 among isogenic iPSC-CMs by Western blot analysis using an antibody detecting the N-terminus of MYBPC3 in all isogenic comparisons, whereas MYBPC3 protein expression was undetectable in 943hom iPSCCMs ( Figure 3D and Figures VE and VF and VIA through VIC). We corroborated these findings by mass spectrometry analysis of isogenic iPSC-CMs ( Figure 3E ). Furthermore, we performed Western blot analysis on protein lysates from EHTs of all isogenic lines to evaluate the protein expression of MYBPC3 in 3D constructs and observed comparable levels of MYBPC3 in EHTs derived from HCM iPSC-CMs when compared with the respective isogenic controls ( Figure VID A, Contraction analysis of iPSC-CM monolayers using a vector-based imaging approach. The relative differences of disease (943het) vs healthy (943cor) were calculated for each respective experiment (n=5). B, iPSC-CMs from 943cor, 943het, and 943hom were treated with dexamethasone (Dex), triiodothyronine (T3), and insulin-like growth factor 1 (IGF1) for 72 hours before contractility analysis (n=3 batches). Analysis was performed using a vector-based imaging approach. C, Analysis of calcium handling properties in isogenic iPSC-CMs (943cor, 943het, and 943hom) using ratiometric measurements of fluorescence after Fura-2 staining under continuous field potential stimulation (n=4/4/6 differentiation batches each, 40 cells per batch). D, Relative expression of ATP2A2 in iPSC-CMs (943cor, 943het, and 943hom; n=3-6 differentiation batches each). E, Representative raw traces of intracellular calcium signaling. HCM, hypertrophic cardiomyopathy; iPSC-CM, induced pluripotent stem cell-derived cardiomyocyte; and sec, seconds. #P<0.1; *P<0.05; **P<0.01. 
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Supplement). We next evaluated a possible expression of truncated MYBPC3 peptides in HCM iPSC-CMs. We did not detect truncated MYBPC3 peptides by Western blot analysis using a validated antibody or by mass spectrometry analysis ( Figure 3D and Figures VE and VF, VIA through VID, and VIIA and VIIB in the online-only Data Supplement). Given the involvement of the UPS in the clearance of the truncated MYBPC3 peptides, 24 we investigated the potential role of the UPS in HCM iPSCCMs harboring PTC mutations. After treating 943hom iPSC-CMs with various proteasome inhibitors ( Figure  VIIC in the online-only Data Supplement), we were still unable to detect truncated MYBPC3 protein in 943hom iPSC-CMs by Western blot analysis ( Figure VIID in the online-only Data Supplement). In contrast, low levels of putative truncated MYBPC3 peptide were detected at the predicted molecular weight of 125 kDa with highsensitivity nanofluidic-immunoassay after proteasome inhibition ( Figure VIIE and VIIF in the online-only Data Supplement). Taken together, these data do not support either a MYBPC3 haploinsufficiency or a truncated MYBPC3 poison peptide hypothesis as the underlying cause of HCM.
RNA Sequencing of MYBPC3 PTC iPSCCMs Reveals a Gene Signature of NMD Activation
To further elucidate the molecular mechanism underlying the pathogenesis of the HCM phenotype associated with MYBPC3 PTC mutation, we next performed RNA sequencing in isogenic iPSC-CMs (943cor versus 943het, ctrl versus ctrl943; Figure VIIIA in the onlineonly Data Supplement). We detected 125 upregulated and 173 downregulated genes in HCM compared with isogenic control iPSC-CMs (Figure 4a and Table IV in A and B, Total MYBPC3, troponin T (TNNT2), and myosin heavy chain 7 (MYH7) mRNA expression in isogenic iPSC-CMs measured by qPCR (943cor, 943het, and 943hom; n=3-4, respectively). C, Fraction of mutant mRNA (mut.) and wild type (WT) within total MYBPC3 mRNA accounts for 32.7% ± 0.6% in 943het iPSCCMs (quantification using RNA-seq data; 943cor and 943het; n=3, respectively). D, Western blot analysis of MYBPC3 protein levels and quantification of MYBPC3 protein expression normalized to αSA in isogenic iPSC-CMs (using Santa Cruz E7 anti-MYBPC3; 943cor and 943het). E, Mass spectrometry analysis of MYBPC3 protein expression in healthy (943cor, ctrl) and HCM (943het, ctrl943) iPSC-CMs (n=4 differentiation batches, respectively). αSA indicates α sarcomeric actin; HCM, hypertrophic cardiomyopathy; iPSC-CM, induced pluripotent stem cell-derived cardiomyocyte; MYBPC3, myosin-binding protein C3; and qPCR, quantitative polymerase chain reaction. #P<0.1; *P<0.05; **P<0.01. 
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mon molecular HCM phenotype in iPSC-CMs carrying MYBPC3 PTC mutations characterized by the activation of the NMD pathway and a HCM gene signature in comparison to isogenic healthy iPSC-CMs.
NMD Inhibition Ameliorates MYBPC3 PTC-Associated Functional and Molecular Phenotypes
To evaluate whether there is a direct interaction between the upregulation of NMD and the observed molecular phenotype in iPSC-CMs, we next used a small-interfering RNA approach to inhibit UPF1, a key component of the NMD pathway. 25 UPF1 is one of the crucial regulators for initiation of NMD in response to mRNA transcripts with a PTC mutation. The recruitment of the SURF complex (SMG1, UPF1, ERF1, and ERF3 factors) because of a PTC mutation distinguishes the PTC from the authentic termination site.
26
SMG1-mediated phosphorylation of UPF1 leads to initiation of mRNA and peptide degradation. 26 In iPSCCMs carrying the p.R943x mutation, UPF1 inhibition resulted in the normalization of the expression of the majority of genes included in the HCM gene signature ( Figure 5A and 5B and Figure XA in the online-only Data Supplement). In contrast, knockdown of UPF1 in isogenic control iPSC-CMs showed no specific regulation of the HCM gene signature ( Figure XB in the online-only Data Supplement). We next investigated whether manipulating the NMD pathway would affect A and B, Regulation of genes contributing to the molecular HCM phenotype by siUPF1 treatment compared with scramble (siSCR) control in 943het iPSC-CMs. A, Genes upregulated in HCM (943het, ctrl) being reversed by NMD inhibition are highlighted in blue, and B, genes downregulated in HCM being reversed by NMD inhibition are highlighted in red (943het iPSC-CMs; n=3 differentiation batches; data are presented as mean log 2 fold change of siUPF1 vs siSCR control ± SEM). C, NMD modulation by UPF1 inhibition resulted in a reversion of calcium handling abnormalities in 943het iPSC-CMs. D, Proposed mechanism of NMD activation by PTC carrying MYBPC3 mRNA resulting in a molecular HCM phenotype and abnormal calcium signaling. Short-term inhibition of UPF1 results in a partial reversion of the HCM phenotypes supporting a direct link between NMD activation and HCM. HCM indicates hypertrophic cardiomyopathy; iPSC-CM, induced pluripotent stem cell-derived cardiomyocyte; MYBPC3, myosin-binding protein C3; NMD, nonsense-mediated decay; and PTC, premature termination codon. *P<0.05; **P<0.01. (Figure 5C ). On the contrary, the disease-specific response of increased Ca 2+ reuptake kinetics on UPF1 inhibition was not observed in the 943cor isogenic control iPSC-CMs ( Figure XC in the online-only Data Supplement). These findings suggest a direct link between MYBPC3 PTC mutation and sustained NMD activation at the molecular level that precedes the emergence of the HCM phenotype ( Figure 5D ). At this stage, these mechanisms are independent of haploinsufficiency on the MYBPC3 protein level or an accumulation of truncated peptides.
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DISCUSSION
MYBPC3 PTC mutations are the most common cause of HCM. 2 Although recent studies have shown that iPSC-CMs recapitulate certain aspects of HCM phenotypes, 8, 20, 27 the mechanistic link between MYBPC3 PTC mutations and the pathogenesis of HCM is still lacking. Several studies have investigated the underlying mechanism of how MYBPC3 PTC mutations lead to HCM, and two separate hypotheses have been proposed: (1) a deleterious truncated peptide, and (2) MYBPC3 haploinsufficiency. Studies using cardiac tissue from patients with HCM harboring MYBPC3 PTC mutations 3, 28 and transgenic animal models 29, 30 suggest that the truncated MYBPC3 peptides are cleared by the ubiquitin-proteasome system. 24, 31 Haploinsufficiency of MYBPC protein has been shown in cardiac samples derived from patients within PTC mutations of MYBPC3. 3 Previous studies comparing HCM to unrelated control iPSC-CMs have yielded conflicting results in regard to MYBPC3 protein haploinsufficiency, 20, 32 most likely reflecting the influence of the genetic background on the iPSC-CM phenotype 33 when comparing nonisogenic iPSCs.
In this study, we combined human iPSCs and genome editing technologies to interrogate the mechanisms underlying the pathogenesis of HCM associated with MYBPC3 PTC mutations in vitro. We demonstrated that HCM iPSC-CMs display aberrant calcium handling properties without evidence for haploinsufficiency of MYBPC3 at the protein level and with absence of any detectable truncated peptides in isogenic iPSCCMs carrying two separate MYBPC3 PTC mutations (p.R943x and p.R1073P_Fsx4) in both 2-dimensional monolayers and 3-dimensional EHT preparations. These results challenge the concept of haploinsufficiency or poison peptides as the underlying mechanisms for HCM caused by MYBPC3 PTC mutations, suggesting that early pathophysiological processes at the molecular level may precede the development of disease. Indeed, we identified a molecular HCM signature characterized by the activation of NMD pathway and the dysregulation of a set of genes involved in major cardiac signaling pathways. The NMD has been shown to be the major pathway involved in clearance of MYBPC3 mRNA with PTC mutations in mice. 4 However, besides its role as a cellular surveillance pathway, NMD also interacts with other major pathways involved in RNA and protein homeostasis 34 and functionally tunes both the transcriptomes and proteomes in mammalian cells. 25 We demonstrated that inhibition of the NMD pathway in HCM iPSC-CMs ameliorates the HCM phenotype at both functional and molecular levels, supporting a role of NMD in the pathogenesis of HCM associated with MYBPC3 PTC mutations.
In conclusion, we have provided the first evidence directly connecting the sustained activation of the NMD pathway and HCM disease development associated with MYBPC3 PTC mutations. Further elucidation of the specific molecular mechanisms linking NMD to HCM holds promise for uncovering valuable new therapeutic targets in HCM.
ARTICLE INFORMATION
